Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of ... 2013; while production volume reached close to 1.84 million tonnes in the same ... of 75.5% of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide ...
(Date:7/28/2015)... -- Tauriga Sciences, Inc. (OTCQB:  TAUG) or ("Tauriga" or ... that its stockholders approved an increase in the number ... from 1,000,000,000 to 2,500,000,000 at its Special Meeting of ... Offices of Nixon Peabody LLP in Midtown Manhattan (the ... shares of common stock represented either by proxy or ...
(Date:7/28/2015)... July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... it has granted to German life sciences entrepreneurs ... and commercialization of biotechnology (collectively, the "Optionee"), an ... allogenic tumor vaccine technology (the "Technology"), including AEZS-120, ... which is ready to enter a Phase 1 ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... , , KNOXVILLE and OAK RIDGE, Tenn., ... Valley ( www.knoxvilleoakridge.com ) see the successful test of Boeing,s 787 ... Innovation Valley is home to Oak Ridge National Laboratory (ORNL), the ... forefront of applied carbon fiber research. , The potential ...
... CITY, Dec. 18 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... biopharmaceutical company focused on oncology and endocrine therapy, today ... ( SNY) dated March 5, 2009 for the development, ... (BPH) for the U.S. market, following the Company,s announcement ...
... , LANSING, Mich., Dec. 18 Neogen Corporation (Nasdaq: ... second quarter of FY 2010, which ended Nov. 30, increased ... 3-for-2 stock split effective Dec. 15, net income in the ... year,s $0.17. Neogen,s second quarter net income of $4,610,000 set ...
Cached Biology Technology:Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 2Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 3AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia 2Neogen Reports 18% Increase in Net Income 2Neogen Reports 18% Increase in Net Income 3Neogen Reports 18% Increase in Net Income 4Neogen Reports 18% Increase in Net Income 5Neogen Reports 18% Increase in Net Income 6Neogen Reports 18% Increase in Net Income 7
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... entomologists are set to meet next week at the ... as the North Central Branch of the Entomological Society ... topics will include public health/bed bug entomology, biocontrol of ... and Sontrol tactics, soybean aphid management, and insect biodiversity ...
... -- It,s a cloak that surpasses all others: a ... the way bacteria and other cells are imaged. ... State University, and his research team are wrapping bacteria ... under electron microscopes. Berry,s method creates a carbon cloak ...
... , This release is available in Spanish ... grass breeder has rediscovered a forage grass that seems just ... of an unusual forage grass led Michael Casler, an Agricultural ... Research Center in Madison, Wis., to identify the grass as ...
Cached Biology News:All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 2All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 3Dairy farmer finds unusual forage grass 2